| 2.47 Data as of May 20 |  +0.035 / +1.44%Today’s Change | 1.17 Today|||52-Week Range 3.00 | +61.11% Year-to-Date |
| Previous close | 2.43 |
| Today’s open | 2.47 |
| Day’s range | 2.44 - 2.56 |
| Volume | 1,166,147 |
| Average volume (3 months) | 2,111,107 |
| Market cap | $202.8M |
| Dividend yield | -- |
| Earnings growth (last year) | -75.00% |
| Earnings growth (this year) | +29.25% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 7.26 |
| Today’s change | Today’s % change | |
|---|---|---|
| PPHMPeregrine Pharmaceut... | +0.29 | +18.83% |
| STSIStar Scientific Inc | +0.12 | +9.37% |
| CTIXCellceutix Corp | +0.03 | +1.49% |
| DRTXDurata Therapeutics ... | -0.03 | -0.42% |
| Next reporting date | August 15, 2013 |
| EPS forecast (this quarter) | -$0.10 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$35.0M |
| Net profit margin | -- |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Mark J. Ahn, PhD, MBA |
Chief Operating Officer & Executive Vice President Mark W. Schwartz, PhD |
Corporate headquarters Lake Oswego, Oregon |
.
